Alnylam Pharmaceuticals, Inc. (ALNY) earnings on October 29, 2026

Before the market opens Q3 2026

More Alnylam Pharmaceuticals, Inc. earnings

Prior outlook: Optimistic Outcome: Missed

Alnylam shares closed 25.13% lower after quarterly results and a Phase 3 TRITON-CM study update caused a sharp selloff.

ALNY price around the earnings

174.00

Change: -25.1%

2026-10-29, 20:00 UTC

End of the measured window
172.55 195.43 218.32 241.20 232.40
Price series around the eventClosing price per minute from before the event to the end of the measured window.
October 29, 2026
  • Price: green if it ends above the starting price; red if it ends below
  • End of the measured window
  • Market open
  • Starting price
Price series around the event

Prior thesis

Prior outlook: Optimistic Outcome: Missed

Thesis published
Results released

The price setup carries the optimistic view, supported by analyst price targets far above current market review levels and positive clinical headlines. Market sentiment is more cautious, and a sharp drop after recent company results tempers the picture.

Context analyzed before publication

Playbook
The average analyst price target sits roughly 58% above current levels, while the stock has recently lagged the broader technology index. Past reactions to company results have been unusually sharp, so swings around results have historically been large.
Trend
Growth expectations hold, but weaker confidence keeps the scenario cautiously optimistic.

Analysts

Drivers

  • Analysts Positive

    The average analyst price target of $368 sits about 58% above the current price, based on 27 analyst opinions that are mostly favorable.

Evidence

Analyst consensus
Buy
Consensus average (1-5)
1.67
Analysts covering the stock
27
Average price target
367.78
Lowest price target
250
Highest price target
536
Upside to price target
58.3%
Revenue growth
66.9%
Forward EPS
12.35
Trailing EPS
5.93
Analyst moves in the last 60 days
7
  • Strong buy: 6
  • Buy: 17
  • Hold: 7
  • Sell: 0
  • Strong sell: 0
Strong buy
6
Buy
17
Hold
7
Sell
0
Strong sell
0
  • October 14, 2026 · Citigroup: Maintains rating (Buy → Buy)
  • October 14, 2026 · Wells Fargo: Maintains rating (Equal-Weight → Equal-Weight)
  • October 8, 2026 · RBC Capital: Maintains rating (Outperform → Outperform)
  • September 30, 2026 · JP Morgan: Maintains rating (Overweight → Overweight)
  • September 21, 2026 · HC Wainwright & Co.: Reiterates rating (Buy → Buy)
  • September 8, 2026 · Jefferies: Maintains rating (Hold → Hold)
  • September 2, 2026 · HC Wainwright & Co.: Reiterates rating (Buy → Buy)

News and sentiment

Drivers

  • News & sentiment Positive

    Phase 1b brezosiran headlines report reductions of up to 83% that grow with the dose, and the company plans further confirmatory study work.

Evidence

Sentiment
Sentiment
Constructive
Mention volume
High
Normalized volume
99%
Messages
30

Technicals

Drivers

  • Technical Negative

    Over 30 days, the stock fell 8.95% while QQQ fell 1.49%, leaving it 7.46 points behind the technology index. In the last 14 days, it gained 3.56%, and the scenario points optimistic.

Evidence

Price when the context was analyzed
232.5
Average true range (ATR)
3.2%
Distance to 52-week high
-51.7%
14-day change (14d)
+3.6%
30-day change (30d)
-8.9%
30-day relative strength
-7.5%
QQQ change (30d)
-1.5%
Nearest support
232
Distance to nearest support
0.2%
Nearest resistance
236.88
Distance to nearest resistance
1.9%
Volume accumulation ratio (14d / 46d)
0.78
  • Mid: 232 (0.2% away, 0.07 ATR, 34 touches)
  • Major: 229.2 (1.4% away, 0.44 ATR, 48 touches)
  • Mid: 225.65 (3% away, 0.91 ATR, 10 touches)
  • Major: 236.88 (1.9% away, 0.58 ATR, 35 touches)
  • Major: 239.1 (2.8% away, 0.88 ATR, 44 touches)
  • Major: 242.65 (4.4% away, 1.35 ATR, 21 touches)

Trends

Evidence

Average earnings surprise
+17.7%
  • July 30, 2026: actual EPS 1.84 vs estimate 2.14 (surprise -14.2%)
  • April 30, 2026: actual EPS 1.99 vs estimate 1.47 (surprise +35.3%)
  • February 12, 2026: actual EPS 1.25 vs estimate 1.5 (surprise -16.5%)
  • October 30, 2025: actual EPS 2.9 vs estimate 1.75 (surprise +66.1%)

Expected move

Drivers

  • Past earnings Negative

    After results on July 30, 2026, the shares moved 28.4% from one close to the next, with an initial reaction of 21.3%.

Implied move
+3.5%
Source
Options chain

Reactions over its last 21 earnings

Median move
3.1%
75th percentile move
7.5%
90th percentile move
15.2%
Up / down moves
9 / 12
Average up move
+4.5%
Average down move
-7.3%

Monitoring and close

What Alnylam Pharmaceuticals, Inc. reported

Status
Finished
Actual EPS16.26
EPS estimate2.25
EPS surprise+623.0%
Revenue$1,458 million
Revenue estimate$1,434 million
Revenue surprise+1.7%

Alnylam reported Q3 2026 revenue of $1.46 billion and adjusted EPS of $16.26, reaffirmed its outlook, and expanded the nucresiran heart trial to about 2,250 patients; shares fell 19%.

Sources (15)

Pre-market second reading after the results

Verdict
Beat expectations

Heading into the open, Results beat expectations on both earnings and revenue and the price is indicating -4.8% pre-market, a move above the stock's usual reaction (about 3%). The figures overturn the prior optimistic scenario. Across our market history, in the 738 similar cases the close held that direction 87% of the time.

How the stock reacted

Outcome
Missed
Consolidated
-25.1%
Max favorable move (MFE)
4.2%
Max adverse move (MAE)
25.9%